Oct 29, 2021

Isogenica attended ELRIG: Drug Discovery October 19-20th 2021

Isogenica’s Research Scientist, David Knight, attended ELRIG: Drug Discovery 2021 where he presented a poster on the latest Isogenica VHH data on VHH drug discovery using synthetic libraries.

Isogenica uses diverse (1e13) fully synthetic camelid domain antibody (VHH) libraries for internal and partnered drug discovery. Humanised synthetic libraries offer several advantages over immunisation or the use of naïve libraries, including diversity and the speed of clone isolation.

To learn more about the benefits of our synthetic libraries and how these can be applied to your projects download the poster here:

Further Information

Isogenica has developed LlamdA™ (single domain VHH) therapeutic antibodies from its proprietary fully synthetic antibody libraries and leveraging its CIS Display and Colibra™ technologies to accelerate the discovery and development process.  Over the last four years Isogenica has entered into eight significant partnerships, leveraging its libraries, technologies and expertise to build a broad pipeline of programs that are now advancing into pre-clinical and early clinical development with our partners.”


Mandeep Sehmi,
Business Development

T +44 1799 533 680